Enhancing the Efficiency and Sustainability of Oligonucleotide Manufacturing

The move from rare-disease programmes to large chronic indications is rewriting the rules of oligonucleotide manufacturing. Infrastructure, synthesis methods, and commercial models built for kilograms are now being asked to deliver tonnes, and the decisions that will determine who keeps pace need to be made as soon as possible.

To confront this, 36 senior experts from industry and academia met across two days of pre-competitive discussion.

Read the full report below

Please enter your email to access content Read now